SUNNYVALE, Calif., Nov. 8 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(TM) Tissue of Origin Test is the focus of two studies featured in poster presentations at this week's 12th Annual Meeting of the Association for Molecular Pathology (November 7-10, Los Angeles). The new genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin.
There are an estimated 200,000 cancer patients each year in the United States who may benefit from diagnostic information to determine the tissue of origin for their cancer. One study showed that, in some cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.
The Pathwork Tissue of Origin Test's proprietary analytics are designed to measure the expression of more than 1600 genes and compare a tumor's genetic "signature" against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix instrument system.
"This test has the potential to be an effective aid in the diagnosis of cancer patients presenting with poorly differentiated and undifferentiated tumors," concluded Federico Monzon, M.D., Methodist Hospital, Houston, TX, (Poster #ST102, Friday, November 9, 1:00-3:00 PM, Constellation and Olympic Ballroom).
Dr. Monzon's clinical validation study ("Validation of a gene
expression-based tissue of origin test applied to poorly differentiated and
undifferentiated cancers") evaluated the performance of the Pathwork Tissue
of Origin Test in a clinical setting. In the study, specimens of 477
metastatic and poorly differentiated and und
|SOURCE Pathwork Diagnostics|
Copyright©2007 PR Newswire.
All rights reserved